The study investigators wanted more data on long-term outcomes in pediatric patients following implantation of a transcatheter Potts shunt (TPS) for treatment of severe pulmonary arterial hypertension ...
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of ...
Pulmonary hypertension life expectancy and prognosis can vary broadly, but have improved in the era of modern treatment.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in combination with other pulmonary ...
Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...
Sotatercept reduced the relative risk of major morbidity and mortality events by 76% compared with placebo. Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with ...
The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...
AJMC: Can you explain the etiology and progression of PAH and the importance of early diagnosis? HASSOUN: Pulmonary arterial hypertension (PAH) refers to World Health Organization (WHO) group 1 ...
Pulmonary arterial hypertension, a disease that leads to worsening lung and heart problems that eventually become life-threatening, is treated with drugs that alleviate symptoms. FDA approval of a new ...
(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in ...
Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback